Age |
55.0±13.4 |
53.3±13.3 |
57.2±13.2 |
0.27 |
Female Sex |
29.1% (39) |
25.6% (21) |
32.7% (18) |
0.36 |
AF type at index procedure |
|
|
|
0.013 |
Paroxysmal |
57.5% (77) |
40.2% (33) |
61.8% (34) |
|
Persistent |
41.0% (55) |
59.8% (49) |
38.2% (21) |
|
Longstanding Persistent |
1.5% (2) |
2.4% (2) |
0% |
|
Baseline ECG in Sinus Rhythm – Index Procedure |
58.2% (78) |
51.2% (42) |
65.4% (36) |
0.1 |
Previous Non-AF ablation |
9.8% (13) |
9.8% (8) |
9.0% (5) |
0.71 |
Previous Alcohol Septal Ablation |
4.5% (6) |
2.4% (2) |
7.3% (4) |
0.17 |
Previous Surgical Myectomy |
10.4% (14) |
15.8% (13) |
1.8%
(1) |
0.008 |
LV Apical Aneurysm |
1.5% (2) |
2.4% (2) |
0% |
0.51 |
Congestive HF |
15.7% (21) |
15.8% (13) |
14.5% (8) |
0.83 |
Hypertension |
25.4% (34) |
19.5% (16) |
32.7% (18) |
0.79 |
Diabetes |
14.2% (19) |
14.6% (12) |
12.7% (7) |
0.54 |
Stroke or TIA |
10.4% (14) |
12.2% (10) |
7.3% (4) |
0.35 |
Vascular Disease |
9.7% (13) |
8.5% (7) |
10.9% (6) |
0.64 |
Chronic Kidney Disease |
3.8% (5) |
3.6% (3) |
5.4% (3) |
0.61 |
Obstructive Sleep Apnoea |
6.7% (9) |
11% (6) |
5.4% (3) |
0.67 |
NYHA Class |
1.8±0.7 |
1.8±0.7 |
1.7±0.7 |
0.91 |
CHA2DS2VASc |
1.5±1.5 |
1.3±1.4 |
1.6±1.6 |
0.21 |
HAS-BLED |
0.8±0.9 |
0.8±0.9 |
0.8±0.9 |
0.39 |
Single antiplatelet therapy |
3.6% (5) |
6.1% (5) |
0% |
0.08 |
Dual antiplatelet therapy |
0 |
0% |
0% |
- |
Apical Hypertrophy |
10.9% (14) |
7.3% (8) |
10.9% (6) |
0.79 |
Moderate to Severe MR |
12.2% (14) |
7.3% (6) |
14.5% (8) |
0.17 |
Restrictive pattern |
21.6% (29) |
23.2% (19) |
18.2% (10) |
0.48 |
Max LVOT gradient (mm Hg) |
14±24 |
9±13 |
21±32 |
0.02 |
Max LV Thickness (mm) |
17±4 |
17±4 |
18±3 |
0.009 |
LA diameter (mm) |
47±7 |
49±7 |
45±6 |
0.5 |
LVEF |
58±9 |
57±10 |
59±9 |
0.017 |